We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vericel Corporation | NASDAQ:VCEL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.89 | -1.86% | 46.94 | 18.00 | 54.59 | 48.41 | 46.75 | 48.00 | 494,551 | 01:00:00 |
|
Michigan
|
|
94-3096597
|
(State or other jurisdiction of
|
|
(I.R.S. employer
|
incorporation or organization)
|
|
identification no.)
|
|
|
|
64 Sidney Street
|
||
Cambridge, MA 02139
|
||
(Address of principal executive offices, including zip code)
|
Large accelerated filer -
o
|
|
Accelerated filer -
x
|
|
|
|
Non-accelerated filer -
o
|
|
Smaller reporting company -
o
|
(Do not check if a smaller reporting company)
|
|
|
COMMON STOCK, NO PAR VALUE
|
|
23,934,124
|
(Class)
|
|
Outstanding at May 3, 2016
|
|
|
|
|
|
|
PART I — FINANCIAL INFORMATION
|
|
|
|
|
|
Item 1.
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
Item 2.
|
||
|
|
|
Item 3.
|
||
|
|
|
Item 4.
|
||
|
|
|
PART II — OTHER INFORMATION
|
|
|
|
|
|
Item 1.
|
||
|
|
|
Item 1A.
|
||
|
|
|
Item 2.
|
||
|
|
|
Item 6.
|
||
|
|
|
|
|
|
|
|
|
|
|
March 31,
|
|
December 31,
|
||||
|
|
2016
|
|
2015
|
||||
ASSETS
|
|
|
|
|
|
|
||
Current assets:
|
|
|
|
|
|
|
||
Cash
|
|
$
|
13,544
|
|
|
$
|
14,581
|
|
Accounts receivable (net of allowance for doubtful accounts of $68 for 2016 and 2015)
|
|
9,669
|
|
|
10,919
|
|
||
Inventory
|
|
1,942
|
|
|
1,379
|
|
||
Other current assets
|
|
662
|
|
|
464
|
|
||
Total current assets
|
|
25,817
|
|
|
27,343
|
|
||
Property and equipment, net
|
|
4,393
|
|
|
4,049
|
|
||
Intangible assets, net
|
|
2,847
|
|
|
2,917
|
|
||
Total assets
|
|
$
|
33,057
|
|
|
$
|
34,309
|
|
LIABILITIES AND SHAREHOLDERS’ EQUITY
|
|
|
|
|
|
|
||
Current liabilities:
|
|
|
|
|
|
|
||
Accounts payable
|
|
$
|
6,293
|
|
|
$
|
7,588
|
|
Accrued expenses
|
|
4,943
|
|
|
3,603
|
|
||
Warrant liabilities
|
|
2,397
|
|
|
757
|
|
||
Other
|
|
136
|
|
|
160
|
|
||
Total current liabilities
|
|
13,769
|
|
|
12,108
|
|
||
Long term debt
|
|
62
|
|
|
71
|
|
||
Total liabilities
|
|
13,831
|
|
|
12,179
|
|
||
COMMITMENTS AND CONTINGENCIES (Note 13)
|
|
|
|
|
|
|
||
Shareholders’ equity:
|
|
|
|
|
|
|
||
Series A non-voting convertible preferred stock, no par value: shares authorized and reserved — 1; shares issued and outstanding — 1
|
|
3,150
|
|
|
3,150
|
|
||
Series B-2 voting convertible preferred stock, no par value: shares authorized and reserved — 39, shares issued and outstanding — 12
|
|
38,389
|
|
|
38,389
|
|
||
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding — 23,891 and 23,789, respectively
|
|
308,512
|
|
|
307,766
|
|
||
Treasury stock — 1,250 shares
|
|
(3,150
|
)
|
|
(3,150
|
)
|
||
Accumulated deficit
|
|
(327,675
|
)
|
|
(324,025
|
)
|
||
Total shareholders’ equity
|
|
19,226
|
|
|
22,130
|
|
||
Total liabilities and shareholders’ equity
|
|
$
|
33,057
|
|
|
$
|
34,309
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2016
|
|
2015
|
||||
Revenues:
|
|
|
|
|
|
|
||
Product sales
|
|
$
|
14,108
|
|
|
$
|
10,849
|
|
Total revenues
|
|
14,108
|
|
|
10,849
|
|
||
Costs and expenses:
|
|
|
|
|
|
|
||
Cost of product sales
|
|
6,560
|
|
|
5,568
|
|
||
Gross profit
|
|
7,548
|
|
|
5,281
|
|
||
Research and development
|
|
3,536
|
|
|
4,377
|
|
||
Selling, general and administrative
|
|
6,004
|
|
|
5,476
|
|
||
Total operating expenses
|
|
9,540
|
|
|
9,853
|
|
||
Loss from operations
|
|
(1,992
|
)
|
|
(4,572
|
)
|
||
Other income (expense):
|
|
|
|
|
|
|
||
Increase in fair value of warrants
|
|
(1,640
|
)
|
|
(317
|
)
|
||
Foreign currency translation (loss) gain
|
|
(10
|
)
|
|
16
|
|
||
Interest income
|
|
5
|
|
|
13
|
|
||
Interest expense
|
|
(3
|
)
|
|
(2
|
)
|
||
Other expense
|
|
(10
|
)
|
|
—
|
|
||
Total other income (expense)
|
|
(1,658
|
)
|
|
(290
|
)
|
||
Net loss
|
|
$
|
(3,650
|
)
|
|
$
|
(4,862
|
)
|
|
|
|
|
|
||||
Net loss per share attributable to common shareholders (Basic and Diluted) (see note 11)
|
|
$
|
(0.24
|
)
|
|
$
|
(0.27
|
)
|
Weighted average number of common shares outstanding (Basic and Diluted)
|
|
22,604
|
|
|
23,786
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2016
|
|
2015
|
||||
Net loss
|
|
$
|
(3,650
|
)
|
|
$
|
(4,862
|
)
|
Other comprehensive loss
|
|
|
|
|
|
|
||
Foreign currency translation
|
|
—
|
|
|
(71
|
)
|
||
Comprehensive loss
|
|
$
|
(3,650
|
)
|
|
$
|
(4,933
|
)
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2016
|
|
2015
|
||||
Operating activities:
|
|
|
|
|
|
|
||
Net loss
|
|
$
|
(3,650
|
)
|
|
$
|
(4,862
|
)
|
Adjustments to reconcile net loss to net cash used for operating activities:
|
|
|
|
|
|
|
||
Depreciation and amortization
|
|
445
|
|
|
328
|
|
||
Stock compensation expense
|
|
488
|
|
|
922
|
|
||
Change in fair value of warrants
|
|
1,640
|
|
|
317
|
|
||
Inventory provision
|
|
17
|
|
|
—
|
|
||
Foreign currency translation loss (gain)
|
|
10
|
|
|
(16
|
)
|
||
Gain on sales of fixed assets
|
|
—
|
|
|
(35
|
)
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
||
Inventory
|
|
(580
|
)
|
|
(85
|
)
|
||
Accounts receivable
|
|
1,250
|
|
|
(975
|
)
|
||
Other current assets
|
|
(229
|
)
|
|
191
|
|
||
Accounts payable
|
|
(1,976
|
)
|
|
460
|
|
||
Accrued expenses
|
|
1,340
|
|
|
(394
|
)
|
||
Other non-current assets and liabilities, net
|
|
(24
|
)
|
|
36
|
|
||
Net cash used for operating activities
|
|
(1,269
|
)
|
|
(4,113
|
)
|
||
Investing activities:
|
|
|
|
|
|
|
||
Expenditures for property, plant and equipment
|
|
(13
|
)
|
|
(353
|
)
|
||
Other
|
|
93
|
|
|
35
|
|
||
Net cash provided by (used in) investing activities
|
|
80
|
|
|
(318
|
)
|
||
Financing activities:
|
|
|
|
|
|
|
||
Net proceeds from issuance of common stock
|
|
258
|
|
|
—
|
|
||
Deferred financing costs
|
|
(97
|
)
|
|
—
|
|
||
Payments on long-term debt
|
|
(9
|
)
|
|
(9
|
)
|
||
Net cash provided by (used in) financing activities
|
|
152
|
|
|
(9
|
)
|
||
Net decrease in cash
|
|
(1,037
|
)
|
|
(4,440
|
)
|
||
Cash at beginning of period
|
|
14,581
|
|
|
30,343
|
|
||
Cash at end of period
|
|
$
|
13,544
|
|
|
$
|
25,903
|
|
|
|
|
|
|
||||
Supplemental cash flow information (non-cash):
|
|
|
|
|
|
|
||
Additions to equipment in process included in accounts payable
|
|
$
|
706
|
|
|
$
|
458
|
|
1.
|
Organization
|
2.
|
Basis of Presentation
|
3.
|
Recent Accounting Pronouncements
|
4.
|
Selected Balance Sheet Components
|
(In thousands)
|
March 31, 2016
|
|
December 31, 2015
|
||||
Raw materials
|
$
|
1,691
|
|
|
$
|
1,228
|
|
Work-in-process
|
232
|
|
|
131
|
|
||
Finished goods
|
19
|
|
|
20
|
|
||
Inventory
|
$
|
1,942
|
|
|
$
|
1,379
|
|
(In thousands)
|
March 31, 2016
|
|
December 31, 2015
|
||||
Machinery and equipment
|
$
|
3,185
|
|
|
$
|
3,280
|
|
Furniture, fixtures and office equipment
|
931
|
|
|
931
|
|
||
Computer equipment and software
|
2,662
|
|
|
2,662
|
|
||
Leasehold improvements
|
2,393
|
|
|
2,393
|
|
||
Construction in process
|
1,140
|
|
|
421
|
|
||
Total property and equipment, gross
|
10,311
|
|
|
9,687
|
|
||
Less: Accumulated depreciation
|
(5,918
|
)
|
|
(5,638
|
)
|
||
|
$
|
4,393
|
|
|
$
|
4,049
|
|
(In thousands)
|
March 31, 2016
|
|
December 31, 2015
|
||||
Commercial rights
|
$
|
3,360
|
|
|
$
|
3,360
|
|
Less: accumulated amortization
|
$
|
(513
|
)
|
|
$
|
(443
|
)
|
|
$
|
2,847
|
|
|
$
|
2,917
|
|
Calendar Years Ending December 31, (In thousands)
|
|
||
2016
|
$
|
210
|
|
2017
|
280
|
|
|
2018
|
280
|
|
|
2019
|
280
|
|
|
2020
|
280
|
|
|
Thereafter
|
1,517
|
|
|
Total
|
$
|
2,847
|
|
(In thousands)
|
March 31, 2016
|
|
December 31, 2015
|
||||
Bonus related compensation
|
$
|
2,584
|
|
|
$
|
1,956
|
|
Employee related accruals
|
1,959
|
|
|
1,341
|
|
||
Accrued expenses
|
16
|
|
|
75
|
|
||
Other
|
384
|
|
|
231
|
|
||
|
$
|
4,943
|
|
|
$
|
3,603
|
|
5.
|
Stock Purchase Warrants
|
|
|
August 2013
Warrants |
Exercise price
|
|
$4.80
|
Expiration date
|
|
August 16, 2018
|
Total shares issuable on exercise
|
|
724,950
|
August 2013 Warrants
|
|
March 31, 2016
|
|
December 31, 2015
|
||||
Closing stock price
|
|
$
|
5.86
|
|
|
$
|
2.58
|
|
Expected dividend rate
|
|
—
|
%
|
|
—
|
%
|
||
Expected stock price volatility
|
|
89.8
|
%
|
|
91.4
|
%
|
||
Risk-free interest rate
|
|
0.8
|
%
|
|
1.3
|
%
|
||
Expected life (years)
|
|
2.38
|
|
|
2.63
|
|
6.
|
Debt
|
7.
|
Stock-based Compensation
|
|
|
Three Months Ended March 31,
|
||||
Service-Based Stock Options
|
|
2016
|
|
2015
|
||
Expected dividend rate
|
|
—
|
%
|
|
—
|
%
|
Expected stock price volatility
|
|
78.7 – 85.5%
|
|
|
80.3 – 88.1%
|
|
Risk-free interest rate
|
|
1.3 – 1.8%
|
|
|
1.5 – 1.9%
|
|
Expected life (years)
|
|
6.1 – 6.3
|
|
|
5.5 – 6.3
|
|
Service-Based Stock Options
|
|
Options
|
|
Weighted
Average
Exercise Price
|
|
Weighted Average
Remaining
Contractual Term
(Years)
|
|
Aggregate
Intrinsic Value
|
|||||
Outstanding at December 31, 2015
|
|
2,523,400
|
|
|
$
|
6.36
|
|
|
8.7
|
|
$
|
5,000
|
|
Granted
|
|
835,480
|
|
|
$
|
3.09
|
|
|
|
|
|
|
|
Exercised
|
|
38,919
|
|
|
$
|
3.06
|
|
|
|
|
$
|
76,687
|
|
Expired
|
|
34,187
|
|
|
$
|
49.45
|
|
|
|
|
|
|
|
Forfeited
|
|
72,340
|
|
|
$
|
3.94
|
|
|
|
|
|
|
|
Outstanding at March 31, 2016
|
|
3,213,434
|
|
|
$
|
5.14
|
|
|
8.8
|
|
$
|
8,116,912
|
|
Exercisable at March 31, 2016
|
|
739,346
|
|
|
$
|
11.20
|
|
|
7.4
|
|
$
|
1,430,199
|
|
8.
|
Fair Value Measurements
|
•
|
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
|
•
|
Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
|
•
|
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
|
|
|
March 31, 2016
|
|
December 31, 2015
|
||||||||||||||||||||||||||||
|
|
|
|
Fair value measurement category
|
|
|
|
Fair value measurement category
|
||||||||||||||||||||||||
(In thousands)
|
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||||||||||
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
Warrant liabilities
|
|
$
|
2,397
|
|
|
$
|
—
|
|
|
$
|
2,397
|
|
|
$
|
—
|
|
|
$
|
757
|
|
|
$
|
—
|
|
|
$
|
757
|
|
|
$
|
—
|
|
9.
|
Shareholders' Equity
|
10.
|
Preferred Stock
|
11.
|
Net Loss Per Common Share
|
|
|
Three Months Ended March 31,
|
||||||
(Amounts In thousands except per share amounts)
|
|
2016
|
|
2015
|
||||
Numerator:
|
|
|
|
|
|
|
||
Net loss
|
|
$
|
(3,650
|
)
|
|
$
|
(4,862
|
)
|
Dividends accumulated on convertible preferred stock
|
|
(1,804
|
)
|
|
(1,590
|
)
|
||
Net loss attributable to common shareholders
|
|
$
|
(5,454
|
)
|
|
$
|
(6,452
|
)
|
Denominator:
|
|
|
|
|
|
|
||
Denominator for basic and diluted EPS:
|
|
|
|
|
|
|
||
Weighted-average common shares outstanding
|
|
22,604
|
|
|
23,786
|
|
||
Net loss per share attributable to common shareholders (basic and diluted)
|
|
$
|
(0.24
|
)
|
|
$
|
(0.27
|
)
|
(In thousands)
|
|
Total
|
|
2016
|
|
2017
|
|
2018
|
|
2019
|
|
More than 5 Years
|
|
||||||||||||
Operating leases
|
|
$
|
26,617
|
|
|
$
|
3,213
|
|
|
$
|
4,899
|
|
|
$
|
4,582
|
|
|
$
|
4,262
|
|
|
$
|
9,661
|
|
|
Purchase commitments
|
|
750
|
|
|
750
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
||||||
Capital leases
|
|
107
|
|
|
32
|
|
|
43
|
|
|
32
|
|
|
—
|
|
|
—
|
|
|
||||||
Total
|
|
$
|
27,474
|
|
|
$
|
3,995
|
|
|
$
|
4,942
|
|
|
$
|
4,614
|
|
|
$
|
4,262
|
|
|
$
|
9,661
|
|
|
|
|
Three Months Ended March 31,
|
||||||
(Amounts In thousands except per share amounts)
|
|
2016
|
|
2015
|
||||
Numerator:
|
|
|
|
|
||||
Numerator of basic and diluted EPS
|
|
$
|
(5,454
|
)
|
|
$
|
(6,452
|
)
|
Add: Increase in fair value of warrants
|
|
1,640
|
|
|
317
|
|
||
Add: Dividends accumulated on convertible preferred stock
|
|
1,804
|
|
|
1,590
|
|
||
Adjusted net loss - Non-GAAP
|
|
$
|
(2,010
|
)
|
|
$
|
(4,545
|
)
|
Denominator:
|
|
|
|
|
||||
Denominator for basic and diluted EPS:
|
|
|
|
|
||||
Weighted-average common shares outstanding
|
|
22,604
|
|
|
23,786
|
|
||
Add: Treasury stock
|
|
1,250
|
|
|
—
|
|
||
Adjusted denominator for basic and diluted EPS
|
|
23,854
|
|
|
23,786
|
|
||
|
|
|
|
|
||||
Adjusted net loss per share (basic and diluted) - Non-GAAP
|
|
$
|
(0.08
|
)
|
|
$
|
(0.19
|
)
|
|
|
Three Months Ended March 31,
|
||||||
(In thousands)
|
|
2016
|
|
2015
|
||||
Total revenues
|
|
$
|
14,108
|
|
|
$
|
10,849
|
|
Cost of product sales
|
|
6,560
|
|
|
5,568
|
|
||
Gross profit
|
|
7,548
|
|
|
5,281
|
|
||
Total operating expenses
|
|
9,540
|
|
|
9,853
|
|
||
Loss from operations
|
|
(1,992
|
)
|
|
(4,572
|
)
|
||
Other expense
|
|
(1,658
|
)
|
|
(290
|
)
|
||
Net loss
|
|
$
|
(3,650
|
)
|
|
$
|
(4,862
|
)
|
|
|
Three Months Ended March 31,
|
||||||
Revenue by product (in thousands)
|
|
2016
|
|
2015
|
||||
Carticel
|
|
$
|
8,811
|
|
|
$
|
7,118
|
|
Epicel
|
|
5,297
|
|
|
3,639
|
|
||
Bone Marrow
|
|
—
|
|
|
92
|
|
||
|
|
$
|
14,108
|
|
|
$
|
10,849
|
|
|
|
Three Months Ended March 31,
|
||||||
(In thousands)
|
|
2016
|
|
2015
|
||||
Gross profit
|
|
$
|
7,548
|
|
|
$
|
5,281
|
|
Gross profit %
|
|
54
|
%
|
|
49
|
%
|
|
|
Three Months Ended March 31,
|
||||||
(In thousands)
|
|
2016
|
|
2015
|
||||
Research and development costs
|
|
$
|
3,536
|
|
|
$
|
4,377
|
|
|
|
Three Months Ended March 31,
|
||||||
(In thousands)
|
|
2016
|
|
2015
|
||||
Dilated Cardiomyopathy
|
|
$
|
1,819
|
|
|
$
|
3,433
|
|
MACI
|
|
553
|
|
|
190
|
|
||
Carticel
|
|
647
|
|
|
478
|
|
||
Epicel
|
|
517
|
|
|
276
|
|
||
Total research and development expenses
|
|
$
|
3,536
|
|
|
$
|
4,377
|
|
|
|
Three Months Ended March 31,
|
||||||
(In thousands)
|
|
2016
|
|
2015
|
||||
Selling, general and administrative costs
|
|
$
|
6,004
|
|
|
$
|
5,476
|
|
|
|
Three Months Ended March 31,
|
||||||
(In thousands)
|
|
2016
|
|
2015
|
||||
Increase in fair value of warrants
|
|
$
|
(1,640
|
)
|
|
$
|
(317
|
)
|
Foreign currency translation (loss) gain
|
|
(10
|
)
|
|
16
|
|
||
Other income
|
|
(10
|
)
|
|
—
|
|
||
Net interest income
|
|
2
|
|
|
11
|
|
||
Total other income (expense)
|
|
$
|
(1,658
|
)
|
|
$
|
(290
|
)
|
|
|
Three Months Ended March 31,
|
||||||
(In thousands)
|
|
2016
|
|
2015
|
||||
Cost of goods sold
|
|
$
|
82
|
|
|
$
|
120
|
|
Research and development
|
|
80
|
|
|
212
|
|
||
Selling, general and administrative
|
|
326
|
|
|
590
|
|
||
Total non-cash stock-based compensation expense
|
|
$
|
488
|
|
|
$
|
922
|
|
1)
|
Remove inappropriate permissions. When the permissions error was located in January 2016, inappropriate access was immediately removed. Information Technology staff responsible for the maintenance of Active Directory Group assignments made changes to the Controller’s permissions and by January 25, 2016, the Controller’s permissions were corrected to remove the incompatible access.
|
2)
|
Enable and/or design reporting functionality that provides an audit trail for journal entries, module access and other relevant user actions. In addition to the corrections to the Controller’s permissions, the FastPath software vendor was contacted to customize an additional report that is needed to document the audit trail / life cycle of each journal entry in the ERP. The new report captures journal entries that originate in the general ledger together with the user that initiated each journal entry, the user the changed each journal entry, and the user that posted each journal entry in the ERP.
|
3)
|
Review remaining conflicts and confirm whether Controller’s review would effectively mitigate the risk associated with the permissions.
|
|
VERICEL CORPORATION
|
|
|
|
|
|
/s/ DOMINICK C. COLANGELO
|
|
Dominick C. Colangelo
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
|
|
|
|
/s/ GERARD MICHEL
|
|
Gerard Michel
|
|
Chief Financial Officer and Vice President, Corporate Development
|
|
(Principal Financial Officer)
|
Exhibit No.
|
|
Description
|
|
|
|
10.1
|
|
Loan and Security Agreement, dated March 8, 2016 between the Company, as borrower, and Silicon Valley Bank, as lender (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on March 9, 2016).
|
|
|
|
10.2†**
|
|
Services Agreement, dated April 5, 2016 between the Company and Dohmen Life Science Services, LLC.
|
|
|
|
31.1**
|
|
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
31.2**
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
32.1**
|
|
Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
32.2**
|
|
Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
|
|
101.INS**
|
|
XBRL Instance Document
|
|
|
|
101.SCH**
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
101.CAL**
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
101.LAB**
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
101.PRE**
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
101 DEF**
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
TERM
|
|
DEFINITION
|
Adverse Event
|
|
Any adverse change in health or “side-effect” that occurs in a person participating in a clinical trial, from the time they consent to joining the trial until a pre-specified period of time after their treatment has been completed.
|
Autologous (Patient Specific)
|
|
Originating from the patient receiving treatment. (Vericel uses only autologous cells).
|
BLA — Biologics License Application
|
|
An application containing product safety, efficacy and manufacturing information required by the FDA to market biologics products in the U.S.
|
CLI — Critical Limb Ischemia
|
|
An atherosclerotic vascular disease characterized by insufficient blood flow in the lower extremities that causes severe pain, tissue loss or both.
|
Controlled Clinical Trial
|
|
A clinical study that compares patients receiving a specific treatment to patients receiving an alternate treatment for the condition of interest. The alternate treatment may be another active treatment, standard of care for the condition and/or a placebo (inactive) treatment.
|
DCM — Dilated Cardiomyopathy
|
|
A chronic cardiac disease where expansion of the patient’s heart reduces the pumping function to a point that the normal circulation of blood cannot be maintained.
|
Double-Blind Clinical Trial
|
|
Clinical trials in which neither the patient nor the physician know if the patient received the experimental treatment or a control/placebo.
|
FDA — Food & Drug Administration
|
|
The U.S. FDA ensures that medicines, medical devices, and radiation-emitting consumer products are safe and effective. Authorized by Congress to enforce the Federal Food, Drug, and Cosmetic Act and several other public health laws, the agency monitors the manufacture, import, transport, storage, and sale of $1 trillion worth of goods annually.
|
GMP — Good Manufacturing Practice
|
|
GMP regulations require that manufacturers, processors, and packagers of drugs, medical devices, some food, and blood take proactive steps to ensure that their products are safe, pure, and effective. GMP regulations require a quality approach to manufacturing, enabling companies to minimize or eliminate instances of contamination, mix-ups, and errors.
|
Hematopoietic Cells
|
|
All of the cells in the blood system including myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells), and lymphoid lineages (T-cells, B-cells, NK-cells).
|
Ischemia
|
|
A shortage or inadequate flow of blood to a body part (commonly an organ or tissue) caused by a constriction or obstruction of the blood vessels supplying it.
|
LVEF — Left Ventricular Ejection Fraction
|
|
The fraction of blood pumped out of the left ventricle with each heartbeat.
|
Mesenchymal stromal cells
|
|
Connective tissue cells that, in the case of bone marrow derived MSCs, function to support blood forming cells and secrete anti-inflammatory factors.
|
M2 anti-inflammatory macrophages
|
|
Specialized blood cells that remove damaged tissue and bacteria and secrete anti-inflammatory factors.
|
Open-label Clinical Trial
|
|
A trial in which both the treating physician and the patient know whether they are receiving the experimental treatment or control/placebo treatment.
|
Orphan Drug Designation
|
|
“Orphan drug” refers to a drug or biologic that is intended for use in the treatment of a rare disease or condition. Orphan drug designation from the U.S. Food and Drug Association (FDA) qualifies the sponsor to receive certain benefits from the Government in exchange for developing the drug for a rare disease or condition. The drug must then go through the FDA marketing approval process like any other drug or biologic which evaluates for safety and efficacy. Usually a sponsor receives a quicker review time and lower application fees for an orphan product.
|
Phase 1 Clinical Trial
|
|
A Phase 1 trial represents an initial study in a small group of patients to test for safety and other relevant factors.
|
Phase 2 Clinical Trial
|
|
A Phase 2 trial represents a study in a moderate number of patients to assess the safety and efficacy of a product.
|
Phase 2b Clinical Trial
|
|
A Phase 2b trial is a moderately-sized Phase 2 trial that is more specifically designed assess the efficacy of a product than a Phase 2a trial.
|
Phase 3 Clinical Trial
|
|
Phase 3 studies are initiated to establish safety and efficacy in an expanded patient population at multiple clinical trial sites and are generally larger than trials in earlier phases of development.
|
Prospective Clinical Trial
|
|
A clinical trial in which participants are identified and then followed throughout the study going forward in time.
|
Randomized Clinical Trial
|
|
A clinical trial in which the participants are assigned randomly to different treatment groups.
|
1 Year Vericel Chart |
1 Month Vericel Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions